Citadel Advisors LLC Acquires Shares of 1,093,782 NextCure Inc (NASDAQ:NXTC)

Citadel Advisors LLC acquired a new stake in shares of NextCure Inc (NASDAQ:NXTC) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 1,093,782 shares of the company’s stock, valued at approximately $16,385,000. Citadel Advisors LLC owned approximately 4.99% of NextCure at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in NXTC. Tower Research Capital LLC TRC purchased a new position in shares of NextCure in the second quarter valued at $96,000. Morgan Stanley bought a new stake in shares of NextCure during the second quarter worth $101,000. Northern Trust Corp bought a new stake in shares of NextCure during the second quarter worth $337,000. Charles Schwab Investment Management Inc. bought a new stake in shares of NextCure during the second quarter worth $386,000. Finally, Hillhouse Capital Advisors LTD. bought a new stake in shares of NextCure during the second quarter worth $1,124,000. 47.47% of the stock is owned by institutional investors and hedge funds.

Shares of NXTC stock traded down $0.93 on Friday, hitting $38.68. The stock had a trading volume of 92,586 shares, compared to its average volume of 67,462. The company has a debt-to-equity ratio of 0.02, a current ratio of 17.05 and a quick ratio of 17.05. The business has a 50 day moving average price of $30.76. NextCure Inc has a one year low of $13.86 and a one year high of $44.69.

NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.15). The company had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.50 million. On average, analysts anticipate that NextCure Inc will post -1.8 earnings per share for the current fiscal year.

NXTC has been the subject of several research analyst reports. Bank of America lifted their target price on NextCure from $27.00 to $44.00 and gave the stock a “buy” rating in a research report on Monday, September 9th. Piper Jaffray Companies lifted their target price on NextCure from $26.00 to $54.00 and gave the stock an “overweight” rating in a research report on Thursday, September 5th. Morgan Stanley lifted their target price on NextCure from $25.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Finally, Zacks Investment Research downgraded NextCure from a “hold” rating to a “sell” rating in a research report on Thursday, September 5th.

NextCure Profile

There is no company description available for NextCure Inc

Featured Story: How to interpret Moving Average Convergence Divergence (MACD)

Want to see what other hedge funds are holding NXTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NextCure Inc (NASDAQ:NXTC).

Institutional Ownership by Quarter for NextCure (NASDAQ:NXTC)

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit